KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Asset Writedowns and Impairment: 2018

Historic Asset Writedowns and Impairment for Aquestive Therapeutics (AQST) over the last 1 years, with Dec 2018 value amounting to $53,000.

  • Aquestive Therapeutics' Asset Writedowns and Impairment fell 85.71% to $6,000 in Q3 2019 from the same period last year, while for Sep 2019 it was $16,000, marking a year-over-year change of. This contributed to the annual value of $53,000 for FY2018, which is N/A change from last year.
  • Aquestive Therapeutics' Asset Writedowns and Impairment amounted to $53,000 in FY2018.
  • In the past 5 years, Aquestive Therapeutics' Asset Writedowns and Impairment ranged from a high of $53,000 in FY2018 and a low of $53,000 during FY2018.
  • Its 1-year average for Asset Writedowns and Impairment is $53,000, with a median of $53,000 in 2018.